Hepatitis C News and Research

Latest Hepatitis C News and Research

Regulus Therapeutics to host educational webinar about microRNA biology

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.

10 Dec 2009

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).

9 Dec 2009

Human Genome Sciences closes public offering of new issued shares

Human Genome Sciences, Inc. today announced the closing of its public offering of 17,825,000 newly issued shares of its common stock at a price to the public of $26.75 per share, which includes 2,325,000 shares sold upon exercise by the underwriters of their option to purchase additional shares. The net proceeds to the Company from the offering are approximately $456.3 million, after deducting the underwriting discount and estimated offering expenses.

9 Dec 2009

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that at approximately $120 million, the hepatitis C virus drug market in Brazil is among the largest emerging pharmaceutical markets for the disease.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Travelers may risk both health and travel insurance coverage by not getting vaccinated

With tens of thousands of people set to travel abroad over the Christmas period, AA Travel Insurance are today urging travellers to be properly vaccinated before travelling.

8 Dec 2009

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk A/S and ZymoGenetics, Inc. today announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, as well as broad intellectual property rights covering IL-21 mAb and the development of other IL-21 antibodies.

From Novo Nordisk 8 Dec 2009

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

La Jolla Pharmaceutical Company (“La Jolla”) today announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corporation (“Adamis”) on December 4, 2009.

8 Dec 2009

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company by Adamis.

7 Dec 2009

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

7 Dec 2009

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection provides the following recap of yesterday's investor conference call, which discussed the Company’s acquisition of intellectual property rights from Los Alamos National Security.

5 Dec 2009

Sudbury & District Public Health Unit nurses reach tentative settlement with employer

Following a long and difficult negotiations process, public health nurses with the Sudbury & District Public Health Unit have reached a tentative settlement with their employer.

4 Dec 2009

New Center for Digestive Care to care for all aspects of digestive disease

The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.

4 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Opinions: Media coverage of HIV/AIDS; WTO and global health; G8, HIV/AIDS; stopping syringe reuse

In a New Republic/NPR opinion piece, Harold Pollack, an associate professor at the University of Chicago School of Social Service Administration, looks at the media's coverage of World AIDS Day. "Almost six thousand people died of AIDS [Tuesday]. ... That it happened to be World AIDS Day was almost incidental. AIDS was certainly incidental to much of the mainstream media.

4 Dec 2009

Tripep receives approval to extend ChronVac-C study

Today Tripep (STO:TPEP) received the approval from the Swedish Medical Products Agency and the local ethical committee to give three patients in the highest dose group in the ChronVac-C® study one additional treatment with the therapeutic vaccine.

3 Dec 2009

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

The University of Pittsburgh's McGowan Institute for Regenerative Medicine, which connects scientists who work on tissue engineering, cell therapies, artificial organs and biodevices, has been awarded a Shared University Research (SUR) Award from IBM ( IBM). The IBM SUR Award will provide IBM computer hardware, software and services to Pitt for its cutting-edge "in silico" biological research, which uses computer simulations to explore biological pathways and test therapeutic interventions.

2 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

Regulus Therapeutics to host educational webinar about microRNA biology

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Human Genome Sciences closes public offering of new issued shares

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Specialty pharmaceutical market: Treatment patterns and product performance

Travelers may risk both health and travel insurance coverage by not getting vaccinated

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

Biomagnetics Diagnostics discusses utilization of acquired Los Alamos National Security intellectual property

Sudbury & District Public Health Unit nurses reach tentative settlement with employer

New Center for Digestive Care to care for all aspects of digestive disease

New SPC3649 drug found effective in treating HCV infections

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Opinions: Media coverage of HIV/AIDS; WTO and global health; G8, HIV/AIDS; stopping syringe reuse

Tripep receives approval to extend ChronVac-C study

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in